Answer
Fever, chills, rash or breathing problems within 24 hours of tafasitamab infusion may indicate an infusion-related reaction, and patients should contact their healthcare professionals if these occur.
Sources for this answer
- MINJUVI 200 mg powder for concentrate for solution for infusionIncyte Biosciences UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 13Document updated
Sources checked